Protein detail
ITAL
Integrin alpha-L (CD11 antigen-like family member A) (Leukocyte adhesion glycoprotein LFA-1 alpha chain) (LFA-1A) (Leukocyte function-associated molecule 1 alpha chain) (CD antigen CD11a)
Protein symbol ITAL | UniProt ID | EVMP score 0.25 |
Frequency 3 | Transmembrane count 1 | Protein classification CD markersFDA approved drug targetsPredicted intracellular proteinsPredicted membrane proteinsTransporters |
Basic Information
Protein Names
Integrin alpha-L (CD11 antigen-like family member A) (Leukocyte adhesion glycoprotein LFA-1 alpha chain) (LFA-1A) (Leukocyte function-associated molecule 1 alpha chain) (CD antigen CD11a)
Protein Class
CD markersFDA approved drug targetsPredicted intracellular proteinsPredicted membrane proteinsTransporters
Protein Function
- Predicted intracellular proteins
- CD markers
- Transporters:Accessory Factors Involved in Transport
- FDA approved drug targets:Small molecule drugs
- FDA approved drug targets:Biotech drugs
Transmembrane
1091..1111; Helical
Transmembrane Count
1
Ensembl
Entrez Gene Symbol
Gene Synonym
CD11ALFA-1LFA1A
Gene Description
Integrin subunit alpha L
Chromosome
16
Position
30472658-30523567
Frequency
3
EVMP Score
0.25
Fluorescence & Localization
Tissue SpecificintestineCell SpecificAstrocytesSingle-Nuclei Brain SpecificleukocyteSecretome LocationIntracellular and membraneSecretome FunctionNo annotated function
Function & Pathway
Protein Function
- Predicted intracellular proteins
- CD markers
- Transporters:Accessory Factors Involved in Transport
- FDA approved drug targets:Small molecule drugs
- FDA approved drug targets:Biotech drugs
Cellular Component
Molecular Function
Biological Process
KEGG
- hsa04015 Rap1 signaling pathway
- KEGG:hsa04514 Cell adhesion molecule (CAM) interaction
- KEGG:hsa04517 IgSF CAM signaling
- KEGG:hsa04518 Integrin signaling
- KEGG:hsa04613 Neutrophil extracellular trap formation
- KEGG:hsa04650 Natural killer cell mediated cytotoxicity
- KEGG:hsa04670 Leukocyte transendothelial migration
- KEGG:hsa04810 Regulation of actin cytoskeleton
- KEGG:hsa05144 Malaria
- KEGG:hsa05150 Staphylococcus aureus infection
- KEGG:hsa05166 Human T-cell leukemia virus 1 infection
- KEGG:hsa05169 Epstein-Barr virus infection
- KEGG:hsa05323 Rheumatoid arthritis
- KEGG:hsa05416 Viral myocarditis
Reactome
- R-hsa-1280218 adaptive immune system
- R-hsa-202733 cell surface interactions at the vascular wall
- R-hsa-1474244 extracellular matrix organization
- R-hsa-109582 hemostasis
- R-hsa-198933 immunoregulatory interactions between a lymphoid and a non lymphoid cell
- R-hsa-168249 innate immune system
- R-hsa-216083 integrin cell surface interactions
- R-hsa-6798695 neutrophil degranulation
- R-hsa-73857 rna polymerase ii transcription
- R-hsa-8949275 runx3 regulates immune response and cell migration
- R-hsa-8878159 transcriptional regulation by runx3
Mediation Categories
Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediationImmune mediation
Relations & Evidence
Enzyme-Mediated Modification
0 records.
Ligand-Receptor Signaling
63 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| transmembrane | transmembrane | Ramilowski_location | No | No | No | Yes | No |
| transmembrane | transmembrane | OmniPath | No | No | No | Yes | No |
| plasma_membrane | plasma_membrane | UniProt_location | No | No | No | Yes | No |
| plasma_membrane | plasma_membrane | Cellinker | No | No | No | Yes | No |
| plasma_membrane | plasma_membrane | OmniPath | No | No | No | Yes | No |
| plasma_membrane_transmembrane | plasma_membrane_transmembrane | Membranome | No | No | No | Yes | No |
| plasma_membrane_transmembrane | plasma_membrane_transmembrane | CSPA | No | No | No | Yes | No |
| plasma_membrane_transmembrane | plasma_membrane_transmembrane | HPMR | No | No | No | Yes | No |
| plasma_membrane_transmembrane | plasma_membrane_transmembrane | OmniPath | No | No | No | Yes | No |
| cell_surface | cell_surface | Surfaceome | No | No | No | Yes | No |
Regulatory Interaction Network
4 records.
| Source Protein Symbol | Source UniProt ID | Target Protein Symbol | Target UniProt ID | Is Directed | Is Stimulation | Is Inhibition | Database | References |
|---|---|---|---|---|---|---|---|---|
| SRC | P12931 | ITAL | P20701 | Yes | Yes | Yes | SIGNOR | SIGNOR:25624455 |
| JAK2 | O60674 | ITAL | P20701 | Yes | Yes | No | SIGNOR | SIGNOR:25624455 |
| ITAL | P20701 | ICAM1 | P05362 | Yes | Yes | No | HPMRWangCellPhoneDBSIGNORHINTBioGRIDIntActDIPSPIKE_LCLit-BM-17 | HINT:11279101SIGNOR:23994464Lit-BM-17:11279101BioGRID:12526797HINT:12208882IntAct:12526797HPMR:16354667IntAct:16595626DIP:16595626Lit-BM-17:12526797HPMR:14507735BioGRID:11786177HINT:12526797HINT:29997244Lit-BM-17:11786177HINT:16595626HINT:11786177HINT:22956999SPIKE_LC:16189514 |
| ITAL | P20701 | AKAP9 | Q99996 | Yes | Yes | No | SIGNOR | SIGNOR:16339516 |
Protein Complex Composition
Sequence, Structure & Domains
Sequences
Length
1,170
Mass
128,770
Sequence
MKDSCITVMAMALLSGFFFFAPASSYNLDVRGARSFSPPRAGRHFGYRVLQVGNGVIVGAPGEGNSTGSLYQCQSGTGHCLPVTLRGSNYTSKYLGMTLATDPTDGSILACDPGLSRTCDQNTYLSGLCYLFRQNLQGPMLQGRPGFQECIKGNVDLVFLFDGSMSLQPDEFQKILDFMKDVMKKLSNTSYQFAAVQFSTSYKTEFDFSDYVKRKDPDALLKHVKHMLLLTNTFGAINYVATEVFREELGARPDATKVLIIITDGEATDSGNIDAAKDIIRYIIGIGKHFQTKESQETLHKFASKPASEFVKILDTFEKLKDLFTELQKKIYVIEGTSKQDLTSFNMELSSSGISADLSRGHAVVGAVGAKDWAGGFLDLKADLQDDTFIGNEPLTPEVRAGYLGYTVTWLPSRQKTSLLASGAPRYQHMGRVLLFQEPQGGGHWSQVQTIHGTQIGSYFGGELCGVDVDQDGETELLLIGAPLFYGEQRGGRVFIYQRRQLGFEEVSELQGDPGYPLGRFGEAITALTDINGDGLVDVAVGAPLEEQGAVYIFNGRHGGLSPQPSQRIEGTQVLSGIQWFGRSIHGVKDLEGDGLADVAVGAESQMIVLSSRPVVDMVTLMSFSPAEIPVHEVECSYSTSNKMKEGVNITICFQIKSLIPQFQGRLVANLTYTLQLDGHRTRRRGLFPGGRHELRRNIAVTTSMSCTDFSFHFPVCVQDLISPINVSLNFSLWEEEGTPRDQRAQGKDIPPILRPSLHSETWEIPFEKNCGEDKKCEANLRVSFSPARSRALRLTAFASLSVELSLSNLEEDAYWVQLDLHFPPGLSFRKVEMLKPHSQIPVSCEELPEESRLLSRALSCNVSSPIFKAGHSVALQMMFNTLVNSSWGDSVELHANVTCNNEDSDLLEDNSATTIIPILYPINILIQDQEDSTLYVSFTPKGPKIHQVKHMYQVRIQPSIHDHNIPTLEAVVGVPQPPSEGPITHQWSVQMEPPVPCHYEDLERLPDAAEPCLPGALFRCPVVFRQEILVQVIGTLELVGEIEASSMFSLCSSLSISFNSSKHFHLYGSNASLAQVVMKVDVVYEKQMLYLYVLSGIGGLLLLLLIFIVLYKVGFFKRNLKEKMEAGRGVPNGIPAEDSEQLASGQEAGDPGCLKPLHEKDSESGGGKD
Alternative Products
Event=Alternative splicing; Named isoforms=3; Name=1; IsoId=P20701-1; Sequence=Displayed; Name=2; IsoId=P20701-2; Sequence=VSP_002738; Name=3; IsoId=P20701-3; Sequence=VSP_042842, VSP_042843
Alternative Sequence
110..192; Missing (in isoform 3); 746; Missing (in isoform 3); 954; Q -> QGVHGLVEMQTSKQILCRPAGDAEHTVGAQEGELPCPWGVSEAFRDNIRAGPCR (in isoform 2)
3D Structural Models
Turn
43..46; 75..77; 93..96; 103..105; 186..188; 398..401; 1082..1086; 1124..1127
Helix
30..32; 169..185; 208..214; 217..221; 233..243; 247..249; 274..276; 288..290; 293..297; 298..302; 307..310; 317..319; 323..330; 370..373; 427..429; 571..574; 1090..1114; 1118..1123; 1137..1147; 1153..1155; 1156..1165; 1167..1170
Beta Strand
34..36; 47..52; 55..60; 69..73; 80..82; 97..101; 108..119; 122..134; 140..143; 155..162; 189..206; 255..265; 279..287; 311..316; 331..333; 352..359; 362..367; 375..380; 387..391; 406..411; 413..416; 419..424; 432..437; 446..452; 462..467; 472..474; 477..482; 493..499; 501..510; 514..516; 523..527; 531..535; 539..543; 549..554; 558..561; 566..570; 583..589; 593..595; 598..603; 606..612
3D Structure
NMR spectroscopy (3); X-ray crystallography (38)
Domain & Motif Annotations
Compositional Bias
1157..1170; Basic and acidic residues
Repeat
31..82; FG-GAP 1; 83..141; FG-GAP 2; 338..389; FG-GAP 3; 390..445; FG-GAP 4; 446..506; FG-GAP 5; 507..563; FG-GAP 6; 567..627; FG-GAP 7
Motif
1115..1119; GFFKR motif
Domain (CC)
The integrin I-domain (insert) is a VWFA domain (PubMed:2537322). Integrins with I-domains do not undergo protease cleavage. The I-domain is necessary and sufficient for interaction with ICAM1 and F11R (PubMed:15528364).
Domain (FT)
156..327; VWFA
Region
1128..1170; Disordered
Protein Families
Integrin alpha chain family
Sequence Similarities
Belongs to the integrin alpha chain family.
Clinical Relevance
Disease Involvement
FDA approved drug targets
Related Diseases
Biomarker
Phase 3; Investigative; Preclinical; Approved; Phase 2
Drug Targets
FDA approved drug targets
Drugs
FLUOROURACILSTAUROSPORINENULLCASEARINONE AEPOETIN ALFARECOMBINANT CD40-LIGANDLIFITEGRASTSIROLIMUSODULIMOMABCASEARINONE BEFALIZUMABBUSULFANHYDROGEN PEROXIDEETOPOSIDETHROMBINANTI-THYMOCYTE GLOBULINCYCLOSPORINEH2O2MONOMETHYL FUMARATECYCLOPHOSPHAMIDE ANHYDROUSROVELIZUMABRECOMBINANT MACROPHAGE INFLAMMATORY PROTEIN-1 ALPHAINTERFERON BETA-1ARECOMBINANT LYMPHOKINECASEARINOL BCLOBETASOL PROPIONATETETRADECANOYLPHORBOL ACETATEANHYDROUS TACROLIMUSRECOMBINANT CHEMOKINERESINIFERATOXIN
Antibody
Interaction Protein
ENSG00000081237ENSG00000090339
Interaction Count
2
Interaction Dataset
intact_biogrid